Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Paravertebral Analgesia for VATS
NCT02670759Terminated
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Mar 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (2 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Intensity of postoperative pain at 24 hours. Started Mar 2016; status: terminated.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02670759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670759.